01 December 2007
The CYP3A5*1/*3 single nucleotide polymorphism (SNP) determines the extent of drug interaction between tacrolimus and fluconazole in renal transplant recipients
H. de Jonge, M. Naesens, Y. Vanrenterghem, D. R. KuypersAnn Transplant 2008; 13(1): 34-35 :: ID: 880191
Abstract
Background: Drug interactions between calcineurin-inhibitors and azole antifungals are characterized by a large clinical variability. The aim of this study was to examine the effect of CYP3A4, CYP3A5 and MDR1 SNPs on changes in tacrolimus trough concentrations and daily dose in renal transplant recipients treated with fluconazole.
Material/Methods: Out of 753 renal transplant recipients treated with tacrolimus, 29 patients were identified who received fluconazole treatment. These patients were genotyped for CYP3A4*1/*1B, CYP3A5*1/*3, MDR1 C3435T and G2677T/A and the effect of these SNPs on tacrolimus trough concentrations and dosing during fluconazole treatment was examined.
Results: Dose-corrected tacrolimus C0 did not increase significantly from baseline (1.26±1.23-fold) in heterozygous CYP3A5*1 carriers (n=6) during fluconazole therapy, as opposed to CYP3A5*3 homozygous patients (n=23) (3.28±2.34-fold; p=0.04 between CYP3A5*3/*3 and CYP3A5*3/*1 genotypes ). CYP3A5*3 homozygotes demonstrated a significant decrease in body weight-corrected tacrolimus dose during fluconazole administration (-54.7±23.7% from baseline, p<0.05) as opposed to heterozygous carriers of CYP3A5*1 (-25.1±29.9%; p=0.07 between CYP3A5*3/*3 and CYP3A5*3/*1 genotypes). These findings were not influenced by fluconazole dose or duration of treatment. More CYP3A5*3 homozygous patients were exposed to tacrolimus C0 ≥15 ng/mL during fluconazole therapy compared to CYP3A5*1 carriers (73.9% vs. 16.7%, p=0.01).
Conclusions: Renal transplant recipients with the CYP3A5*3/*3 genotype (non-expressers), are more susceptible for fluconazole-induced inhibition of tacrolimus metabolism as opposed to CYP3A5*1 carriers (expressers). Identification of this genetic determinant affecting the extent of this CYP3A-mediated drug interaction could potentially help to better manage drug interactions between tacrolimus and fluconazole.
Keywords: Tacrolimus, transplant, Broca
In Press
04 Aug 2022 : Original article
Long-Term Patency of All-in-One Sleeve Patch Graft Venoplasty in 16 Patients Who Underwent Living Donor Liv...Ann Transplant In Press; DOI: 10.12659/AOT.936888
22 Jul 2022 : Original article
Diagnostic Role of Tumor Markers for Hepatocellular Carcinoma in Liver Transplantation Candidates: An Analy...Ann Transplant In Press; DOI: 10.12659/AOT.936937
22 Jul 2022 : Original article
Development of a Novel Model for Predicting Postoperative Short-Term Outcome in Patients with Hepatitis B-R...Ann Transplant In Press; DOI: 10.12659/AOT.936732
22 Jul 2022 : Original article
Leucine-Rich Alpha-2-Glycoprotein (LRG-1) as a Potential Kidney Injury Marker in Kidney Transplant RecipientsAnn Transplant In Press; DOI: 10.12659/AOT.936751
Most Viewed Current Articles
26 Jan 2022 : Review article
Recurrence of Hepatocellular Carcinoma After Liver Transplantation: Risk Factors and Predictive ModelsDOI :10.12659/AOT.934924
Ann Transplant 2022; 27:e934924
29 Dec 2021 : Original article
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588
24 Jul 2020 : Review article
Kidney Transplantation in the Times of COVID-19 – A Literature ReviewDOI :10.12659/AOT.925755
Ann Transplant 2020; 25:e925755
15 Mar 2022 : Case report
Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...DOI :10.12659/AOT.935860
Ann Transplant 2022; 27:e935860